Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
U.S. FDA inspection at Indrad facility resulted in 5 observations, including repeat observations from prior inspection. Management expects resolution by October but acknowledges higher approval threshold given facility history.
U.S. business is pre-R&D break-even currently. Management cannot provide timeline for post-R&D profitability, stating it depends on new NDA approvals spanning 2-3 years. Mid-single digit price erosion continues.
Takeda has licensed Vonoprazan non-exclusively to multiple players including Zydus and Dr. Reddy's. While Torrent's Kabvie launched first and holds rank #1 as of June 2024, competitive pressure may intensify and impact market share trajectory.
Brazilian Real depreciated ~5% in Q1 impacting reported revenues. Management states expenses also decline proportionally and Brazil represents only 10% of revenue, but further depreciation could affect profitability.
